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Abstract: Our understanding o
underlying the disease process in patients with thalassaemia intermedia (TI) has substantially 
increased over the past decade. TI encompasses a wide clinical spectrum of beta
phenotypes. Some TI patients are asymptomatic until adult life, whereas others are 
symptomatic from as young as 2 years of age. A number of clinical complications commonly 
associated with TI are rarely seen in thalassaemia major, including extramedullary 
hematopoiesis, leg ulcers, gallstones, thrombosis and pulmonary hypertension. 
number of options currently available for managing patients with TI, including transfusion 
therapy, iron chelation therapy, modulation of foetal haemoglobin production and 
haematopoietic stem cell transplantation. However, a
for an orchestrated optimal treatment plan. 
Introduction: Thalassaemia was defined as 
a clinical entity in 1925 by Dr. Thomas B. Cooley 
at the annual meeting of the American Pediatric 
Society where he presented five young children 
with severe anaemia, splenomegaly, 
bone abnormalities1. Almost all patients with 
thalassaemia syndromes were later classified as 
having thalassaemia minor or thalassaemia major 
(TM). However, a small number of patients did not 
fit into this categorical distribution. Sturgeon was 
the first to describe this group in the Amer
literature. He suggested the term thalassaemia 
intermedia (TI) to describe patients who had clinical 
manifestations that are too severe to be termed 
minor and too mild to be termed major
www.mjhid.org ISSN 2035-3006 
 
2 
-Oncology Division, American University of Beirut Medical Centre, 
 
, Hematology-Oncology Division, Department of Internal 
. Phone: +961-1-350000; Fax: +961
 DOI 10.4084/MJHID.2009.004 
 
), which permits unrestricted use, distribution, and reproduction in any 
. 
f the molecular and pathophysiological mechanisms 
t present, there are no clear guidelines 
 
and peculiar 
β-
ican 
2
. Ever since, 
our knowledge of the molecular basis and 
pathophysiology of TI has progressed significantly 
in the last decade, including an increased 
understanding of the genetic mutations
the TI phenotypes3,4. The clinical presentation and 
sequelae of TI span a wide spectrum of severity. 
The natural history of the disease allows the 
emergence of several complications that are 
relatively unique to TI compared to TM
the optimal course of management for TI patients 
has been hard to identify and several controversies 
remain regarding the best treatm
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treatment options and insights onto future 
perspectives are discussed.   
 
Molecular Understanding. The clinical 
manifestations of thalassaemia result from defects 
in one of two types of haemoglobin (Hb) 
polypeptide chains (alpha or beta). For Hb to 
function properly, the number of alpha-chains must 
precisely match the number of beta-chains; 
thalassaemia is caused by an imbalance in globin 
chain synthesis. The beta-thalassaemias, including 
TI, arise from defective gene function leading to the 
partial suppression of beta-globin protein 
production. The extent of suppression varies from 
patient to patient and dictates the clinical severity of 
disease. Most TI patients are homozygotes or 
compound heterozygotes for beta-thalassaemia, 
meaning that both beta-globin loci are affected3. 
Less commonly, only a single beta-globin locus is 
affected, the other being completely normal1. The 
mild clinical characteristics of TI compared with 
TM major result primarily from three different 
mechanisms3,7:  
• Inheritance of a mild or silent beta-chain 
mutation. Rather than a complete absence of beta-
chain synthesis, the level of synthesis is subnormal. 
This leads to a smaller imbalance between the 
number of alpha-and beta-chains compared with an 
absence of beta-chains. 
• Co-inheritance of determinants associated 
with increased gamma-chain production. The 
increased number of gamma-chains helps to 
neutralize the large proportion of unbound alpha-
chains. 
• Co-inheritance of alpha-thalassaemia. 
This helps to suppress the synthesis of alpha-chains, 
causing less of an alpha/beta-chain imbalance.  
The phenotype of TI may result from the 
increased production of alpha-globin chains by a 
triplicated or quadruplicated alpha genotype 
associated with beta-heterozygosity8,9,10. Table 1 
shows β-globin mutations in TI and TM that have a 
direct effect on modifying the amount of excess 
alpha-chains, such as inheritance of abnormal 
alpha- or gamma-chain genes. Tertiary modifiers 
are polymorphisms occurring at loci involved in 
bone, iron and bilirubin metabolism which can 
affect clinical expression, although these are 
thought to be of relatively little importance. Recent 
studies of the JAK2 cytoplasmic tyrosine kinase, 
which has a vital role in signal transduction from 
several haemopoietic growth factor receptors, 
revealed a V617F mutation that was implicated in a 
variety of diseases mainly related to myelo-
proliferative disorders including polycythaemia 
vera, essential thrombocythaemia, and idiopathic 
myelofibrosis. TI patients, however, do not show 
increased expression of this mutation11.  
Table 1. Prevalent beta-globin mutations in 
thalassaemia intermedia and thalassaemia major in 
patients of Mediterranean origin7. 
 
Environmental factors including social 
conditions, nutrition and the availability of medical 
care have also been implicated as key players in the 
phenotypic variability of TI12.  
A number of studies have attempted to 
classify patients with TI according to the severity of 
their condition, although these studies have had 
only limited success13,14. A recent study described 
the development of a phenotype scoring system that 
successfully sub-classified TI patients into three 
separate groups: mild, moderate or severe 15. The 
severity of TI was graded according to a number of 
clinical features, such as age at presentation, 
severity of anaemia, extent of growth retardation 
and bone marrow hyperplasia, blood transfusion 
requirements and need for splenectomy. This 
classification could prove useful for relating 
genotype to phenotype and for developing separate 
treatment guidelines for different disease severities. 
However, further studies would be required to 
confirm the reliability and utility of this approach.  
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Although the clinical phenotypes of 
thalassaemia minor, intermedia and major differ, 
there are some similarities. There is an increasing 
awareness of the need for accurate diagnosis in 
order to achieve optimal patient management and to 
avoid over or under treatment3,16. The accurate 
identification of TI versus thalassaemia minor and 
TM can be difficult if based on clinical presentation 
alone, although certain differentiating parameters 
have been established. In general, TI is 
characterized by Hb levels maintained around 7–10 
g/dL without the need for regular blood 
transfusions, by more severe red blood cell (RBC) 
abnormalities than thalassaemia minor, by a varying 
degree of spleen enlargement, and by skeletal 
changes such as expansion of the facial bones and 
obliteration of the maxillary sinuses, which causes 
protrusion of the upper jaw5,6,16. Criteria for 
differentiating TM from TI at presentation are 
summarised in Table 2. 
 
Pathophysiology. Three main factors are 
responsible for the clinical manifestations of TI: 
ineffective erythropoiesis, chronic haemolytic 
anaemia and iron overload. The severity of clinical 
sequelae primarily depends on the underlying 
molecular defects. Alpha-chains are highly unstable 
and precipitate within erythroid precursors in the 
bone marrow, causing membrane damage and cell 
death – this is ineffective erythropoiesis17. 
Hypertrophy of erythroid marrow in medullary and 
extramedullary sites, a consequence of severe 
ineffective erythropoiesis, results in characteristic 
deformities of the skull and face and may also cause 
cortical thinning and pathological fractures of long 
bones 16,18. The degree of ineffective erythropoiesis 
is the primary determinant of the development of 
anaemia, while peripheral haemolysis of mature 
RBCs and an overall reduction in Hb synthesis are 
secondary. However, haemolysis per se has been 
linked to the development of a hypercoagulable 
state and pulmonary hypertension (PHT) in this 
patient population 19,20. Damaged circulating RBCs 
expose negatively charged phosphatidyl-serine 
residues through the ‘Flip-Flop’ phenomenon 21. 
These along with activation of platelets, endothelial 
cells and monocytes along with dysfunction of the 
coagulation system have been associated with 
thromboembolic phenomenon, especially in 
splenectomised TI patients21. Moreover, haemolysis 
carries a role in the dysregulation of nitric oxide 
(NO) homeostasis which is correlated with PHT and 
probably thrombotic phenomena22 (Figure 1).  
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In contrast to patients with TM, in whom 
iron loading occurs mainly as a result of transfusion 
therapy, patients with TI accumulate iron primarily 
due to increased intestinal iron absorption23. The 
chronic anaemia and ineffective erythropoiesis that 
are characteristic of TI are associated with reduced 
expression of hepcidin, a hepatic peptide that plays 
a central role in iron homeostasis23. Recent studies 
indicate that growth and differentiation factor 15 
(GDF15), secreted by erythroid precursors, is 
significantly increased in patients with TM, 
inhibiting hepcidin production24. In addition, other 
studies indicate that hypoxia-inducible transcription 
factors (HIFs) control iron homeostasis by 
coordinating the downregulation of hepcidin and 
the upregulation of erythropoietin and ferroportin. 
Under normal conditions, HIFs play a useful role by 
mobilizing iron and supporting erythrocyte 
production in response to anaemia/hypoxia25-27. 
However, the same mechanism may contribute to 
the harmful accumulation of iron in response to the 
chronic anaemia of TI. The combination of 
ineffective erythropoiesis (leading to increased 
GDF15) and chronic anaemia/hypoxia (altering the 
expression of HIF) results in hepcidin suppression, 
increased iron absorption and increased release of 
recycled iron from the reticuloendothelial (RE) 
system. This results in depletion of macrophage 
iron, and relatively low levels of serum ferritin. The 
situation in TI is similar to that seen in patients with 
hereditary hemochromatosis syndromes, which is 
characterized by impaired hepcidin production 
(Figure 2).  
By contrast, in transfused TM patients iron 
is preferentially distributed to the RE system, 
stimulating ferritin synthesis and its release to the 
circulation and leading to high serum ferritin 
levels28. Blood transfusions modify hepcidin 
production by altering all three factors responsible 
for the clinical manifestations of TI described above 
namely: (i) by correcting anaemia, transfusion 
therapy will suppress ineffective erythropoiesis and 
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the associated increase in GDF15; (ii) by correcting 
anaemia, blood transfusions will prevent the 
hypoxia responsible for increased HIF production 
and hypoxia-associated suppression of hepcidin; 
and (iii) increased body iron and transferrin 
saturation will stimulate hepcidin production. The 
result will be a relative increase in hepcidin 
production in polytransfused TM patients 
countering the hepcidin-inhibitory effects of 
anaemia and ineffective erythropoiesis. These 
considerations may explain the differences in iron 
homeostasis characterizing TM compared with 
untransfused TI patients. Thus, although the rate of 
iron loading may be slower than that in patients 
with TM, TI patients will inevitably suffer from 
iron overload which in turn can cause a number of 
serious complications including cardiac failure and 
endocrine abnormalities such as diabetes mellitus 
and hypogonadism. 
 
Clinical Sequelae. As a consequence of the 
aforementioned pathophysiology, several 
complications have been identified in patients with 
TI. Some of these complications have been termed 
unique to TI as compared to TM, especially in the 
splenectomised, transfusion naïve patient (Table 3). 
Cholelithiasis Gallstones are much more 
common in TI than in TM because of ineffective 
erythropoiesis and peripheral haemolysis. Recently, 
unrelated genetic factors such as uridine 5’-
diphospho-alpha-D-glucose (UDPG) deficiency 
(Gilbert’s syndrome) have been reported to increase 
gallstone formation in patients with thalassaemia29. 
For this reason, the gallbladder should be inspected 
during splenectomy and a cholecystectomy 
performed if necessary, particularly if the patient is 
experiencing symptomatic gallstones. This should 
be undertaken to prevent cholecystitis, which can 
have serious consequences in the splenectomised 
patient. 
Extramedullary haematopoiesis. Extra-
medullary haematopoiesis (EMH) is a 
compensatory mechanism where bone marrow 
activity increases in an attempt to overcome the 
chronic anaemia of TI, leading to the formation of 
erythropoietic tissue masses that primarily affect the 
spleen, liver and lymph nodes. These masses can be 
detected by magnetic resonance imaging (MRI). 
They may cause neurological problems such as 
spinal cord compression and paraplegia, and 
intrathoracic masses30,31. Extramedullary haemato-
poiesis can be managed by radiotherapy (since 
haematopoietic tissue is highly radiosensitive)32, 
transfusion therapy or hydroxyurea30,33,34. 
Leg ulcers. Leg ulcers are more common in 
older than in younger patients with TI. It is unclear 
why ulcers develop in some patients who are 
maintained at relatively low Hb levels and have the 
same amount of foetal Hb (HbF) as others in whom 
ulcers do not develop. The skin at the extremities of 
elderly TI patients can be thin due to reduced tissue 
oxygenation, and this makes the subcutaneous 
tissue fragile and increases the risk of lesions from 
minimal trauma. Once an ulcer has started to 
develop it is very painful and difficult to cure, 
although regular blood transfusions may provide 
some relief in persistent cases. Simple measures 
may be beneficial, such as keeping the patient’s legs 
and feet raised above the level of the heart for 1–2 
hours during the day or sleeping with the end of the 
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bed raised. Zinc supplementation35 and 
pentoxifylline, which alters the rheological 
properties of the RBCs36, can help accelerate the 
healing of ulcers. Hydroxyurea also has some 
benefit, either alone or in combination with 
erythropoietin 37. In addition, the use of an oxygen 
chamber can provide moderate relief since tissue 
hypoxia may be an underlying cause of the 
ulceration 38. 
Thromboembolic events. Taher et al.39 
analyzed data from 8860 thalassaemia patients 
(6670 TM and 2190 TI). In this study 
thromboembolic events (TEE) occurred 4.38 times 
more frequently in TI than TM patients, with more 
venous events occurring in TI and more arterial 
events occurring in TM. In another series of TI 
patients, 24 patients (29%) developed either deep 
vein thrombosis (DVT), pulmonary embolism, or 
portal vein thrombosis during a 10-year follow up 
40
. In a recent survey involving nine Italian pediatric 
thalassaemia centres, TEE was observed in 4% of 
683 patients with TM and in 9.6% of 52 patients 
with TI41. Studies collectively revealed that the 
incidence of TEE is higher in splenectomised 
patients 39,40. The incidence of overt stroke in TI 
patients is low (8); however, a study done to assess 
the rate of asymptomatic brain damage in patients 
with benign haemoglobinopathies reported that 
37.5% of patients with TI showed silent brain 
ischemia42. 
Pulmonary hypertension and congestive 
heart failure. Pulmonary hypertension (PHT) is 
prevalent in patients with TI (59.1%)20, and is 
thought to be the primary cause of congestive heart 
failure in this patient population. A retrospective 
analysis showed that splenectomised females with 
significant anaemia, thrombocytosis and elevated 
ferritin levels, were at greatest risk for developing 
PHT43. Preliminary results have demonstrated that 
PHT is reversible by blood transfusion and 
treatment with aspirin and warfarin. Several 
echocardiographic studies have confirmed that 
cardiac ejection fraction is rarely affected in TI44. 
Nevertheless, patients with TI often have an 
increased cardiac output, and left ventricular wall 
dimensions proportional to the dilutional volume 
overload secondary to chronic anaemia45.  
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As anaemia and iron overload are 
uncommon in well-transfused and chelated TM 
patients, they are likely to be at the heart of the 
pathophysiology of PHT. A recent study 
demonstrated a significant correlation between iron 
overloading in the liver and pulmonary artery 
systolic pressure independent of left ventricular 
filling pressures 46. Regular transfusion and iron 
chelation therapy is therefore indicated in TI 
patients who are well-stratified according to the 
early detection of PHT indices. Sildenafil has also 
been successfully used to treat PHT47, although data 
from large patient numbers are lacking in TI. 
Pregnancy and related complications. 
Women with TI may have spontaneous successful 
pregnancies although complications during 
pregnancy may occur48. The chronic anaemia of TI 
can cause an increase in spontaneous abortions, pre-
term labour and intrauterine growth retardation, 
while endocrine complications due to haemo-
siderosis are common49. The course and outcome of 
19 pregnancies was assessed in 16 women with 
thalassaemia, including four with TI50. All 
pregnancies were uneventful and elective Caesarean 
section was performed in each case. The mean birth 
weight of the babies was 3000 g and all were 
normal except for one case of omphalocele. The 
largest study to date assessed 44 TI women who had 
83 pregnancies, all spontaneous, 30 from Lebanon 
and 53 from Italy51. These pregnancies resulted in 
20.5% abortions, 77.1% live-births and 2 
intrauterine foetal deaths at 26 and 36 weeks’ 
gestation. The mean gestational age at delivery was 
36.5 weeks and mean birth weight was 2551 g. In 
pregnancies progressing > 20 weeks’ gestation, pre-
term delivery and intrauterine growth restriction 
(IUGR) were noted in 31.8% and 24.2% of cases, 
respectively. In those complicated by IUGR, 
Caesarean delivery (CS) rate was 87.5%. Two 
women (Italy) developed severe alloimmune 
haemolytic anaemia. One progressed to cardiac 
failure at 35 weeks’ gestation and had CS. The 
other underwent CS for IUGR and non-reassuring 
foetal heart monitoring and was scheduled for a 
splenectomy postpartum. Worsening alloimmune 
anaemia also developed in 2 women from Lebanon 
who required splenectomy within eight weeks 
postpartum. Transfusion was required in 35/44 
women during pregnancy (79.5%), with 27.3% 
requiring transfusion during pregnancy for the first 
time. The lowest mean Hb level was 6.7±2.0 vs. 
8.3±1.2 g/dL in Lebanon and Italy respectively. The 
average ferritin level before pregnancy was 885.2 ± 
658.9 vs.1232.8 ± 902.9 µg/L after pregnancy. In 
total, CS was performed in 48 pregnancies (72.7%), 
the indications being elective (41.7%), repeat 
(31.2%) and obstetrical (27.1%). Pregnancy 
outcome was similar between Lebanon and Italy 
with the exception of a significantly higher rate of 
live births in Italy51.   
Folic acid deficiency is common in TI and 
occurs due to poor absorption, low dietary intake, 
or, most significantly, an increased demand for folic 
acid from active bone marrow. This is a particular 
concern in pregnancy since deficiency can cause 
neural tube defects, such as spina bifida, in the 
growing foetus. During pregnancy, women with TI 
should therefore be given oral folic acid 
supplementation (around 1 mg/day), and should be 
carefully monitored in order to assess the need for 
transfusion therapy and to avoid haemodynamic 
compromises. The major fear of initiating 
transfusions during pregnancy is the development 
of alloantibodies. These can aggravate anaemia and 
progress into severe haemolytic anaemia refractory 
to transfusions and thus increase the complication 
rate. CS may be required in TI patients due to the 
associated cephalopelvic disproportion secondary to 
skeletal deformity and short stature, especially in 
non-transfused women. Splenectomy is usually 
performed in TI women for decreased levels of 
haemoglobin, hyperactivity of the spleen, 
leukopenia and symptomatic thrombocytopenia5,6.  
 
Management. There are a number of 
options currently available for managing patients 
with TI, including splenectomy, transfusion 
therapy, iron chelation therapy, modulation of HbF 
production and haematopoietic stem cell 
transplantation. 
Splenectomy. As per expert opinion, the 
current indications for splenectomy in TI include 
growth retardation or poor health, leukopenia, 
thrombocytopenia, increased transfusion demand, 
or symptomatic splenomegaly6. Clinical 
observations, however, have suggested that 
splenectomy in TI can contribute to an increased 
susceptibility to TEE and PHT39,40,43. This calls for a 
review of splenectomy as a procedure of choice, 
especially with its potential role in increasing TI-
related complications and the inherent risk of 
infection associated with the procedure even for 
individuals without haematological disorders52.  
Transfusion and iron chelation therapy. In 
patients with TM, a remarkable improvement in life 
expectancy and prevention of morbidity has been 
achieved in recent decades 53. This is mainly 
attributed to improved methods of blood 
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transfusion, better understanding of iron toxicity, 
and evolution in iron chelation therapy53. On the 
other hand, TI has been regarded as a clinical entity 
with limited complicationsso as the general 
approach was to avoid early blood transfusions and 
the associated need for chelation therapy. However, 
increasing evidence is delineating the benefit of 
transfusion therapy in decreasing the incidence of 
complications as PHT, TEE, and EMH, to name a 
few30,39,54. Thus although the common practice was 
to initiate transfusion when complications ensue, it 
may be worthwhile start transfusion therapy earlier 
as a preventive approach which will also help 
alleviate the increased risk of alloimmunisation 
with delayed initiation of transfusion55. Although 
earlier introduction of blood transfusions will 
increase the rate of iron accumulation, effective 
methods of iron chelation are now available 56,57, 
and the benefits of transfusion therapy would 
greatly outweigh the cost and inconvenience of iron 
chelation therapy.  
The initiation of iron chelation therapy in 
patients with TI depends not only on the amount of 
excess iron, but also on the rate of iron 
accumulation, the duration of exposure to excess 
iron and various other factors in individual patients. 
A direct assessment of LIC is recommended, either 
by biopsy or by a non-invasive method such as R2 
MRI. Where LIC measurement is not possible, 
threshold serum ferritin values of 400−500 ng/mL 
(which are lower than those generally accepted in 
patients with TM) could be considered as an 
indicator for initiation of iron chelation therapy. 
Chelation therapy should generally be initiated if 
LIC exceeds 7 mg/g dry weight of liver tissue, 
however lower levels of LIC for initiation of 
chelation therapy must be considered particularly 
now with the availability of oral iron chelators 6. 
Modulation of foetal haemoglobin 
production. Increasing the synthesis of HbF can 
help alleviate anaemia and therefore improve the 
clinical status of patients with TI 58. Production of 
HbF is reactivated during recovery from marrow 
suppression after treatment with cytotoxic drugs, 
therefore it is postulated that these agents may alter 
the pattern of erythropoiesis and increase the 
expression of gamma-chain genes. Several 
cytotoxic agents with this effect have been 
identified, including cytosine arabinoside and 
hydroxyurea59-61. Recently published results from 
Iran, evaluating six years of hydroxyurea therapy in 
transfusion dependent patients with TI, are 
encouraging. A significant decrease in the need for 
blood transfusions was observed in many patients; 
the need was completely obviated in some 
patients62. Erythropoietin has also been shown to 
increase HbF levels in some patients with TI58. 
Preliminary trials with intravenous and oral butyric 
acid derivatives have shown increases in foetal and 
total Hb levels in patients with TI63-66, and the 
acceptable safety profile of these agents makes 
them promising therapeutic targets. It is unclear 
how butyrates stimulate gamma-globin production 
or why some patients respond to treatment while 
others do not. 
However, the overall trial results with HbF-
stimulating agents are somewhat disappointing. 
Studies using combined treatments have shown 
greater promise than the individual agents alone67. 
Further clinical evaluation is required to clarify the 
value of this approach, especially in view of the 
reduced oxygen delivery capacity of HbF, as this 
might favour the implementation of a target Hb 
level higher than 10 g/dL in response to increased 
need (e.g. PHT, coronary heart disease and chronic 
obstructive pulmonary disease (COPD)) and an 
increased ratio of HbF/HbA. 
Haematopoietic stem cell transplantation.  
Haematopoietic stem cell transplantation (HSCT), 
where the marrow of an affected patient is replaced 
from the stem cells of an uaffected donor, is an 
established treatment for beta-thalassaemia. 
Although successful HSCT can offer a cure, it can 
be unsuccessful (e.g. if the thalassaemia returns), 
may lead to complications (e.g. graft-versus-host 
disease, growth impairment, neurological 
complications), and can even result in death 68-71; 
the risk for a failed transplantation depends 
primarily on the health and age of the patient. The 
decision as to which patients are eligible for 
transplantation is complex and is related to both the 
quality of life and expected survival-time of the 
transplanted patient, when compared with 
supportive care only. This is particularly relevant in 
patients with TI, especially in those who are only 
mildly affected. Due to the risks involved, 
transplantation is considered appropriate only for 
patients with a human leukocyte antigen (HLA)-
matched donor, which comprises only 30–40% of 
all beta-thalassaemia patients, at most72. As HLA 
type is genetically determined, there is a 25% 
chance that any two siblings will be a match. 
 
Conclusion. Our understanding of the 
molecular and pathophysiological mechanisms 
underlying the disease process in patients with TI 
has substantially increased over the past decade. 
Today, a large body of evidence documents the 
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incidence and consequences of the different clinical 
complications associated with the disease. Although 
there are still currently no clear guidelines for the 
optimal management plan of this disease entity, the 
emerging body of evidence looks promising. 
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